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Abstract
A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for 
Alzheimer’s disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of 
antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or 
immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA 
antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD 
patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL 
in serum samples obtained from Alzheimer’s Disease Neuroimaging Initiative (ADNI). Serum 
Correspondence: Paul A. Hyslop, Arkley BioTek Research Labs, 4444 Decatur Blvd., Ste. 300, Indianapolis, IN 46241, USA., Tel: +1 
013174890150., physlop@arkleybiotek.com.
*Deceased.†Clinical data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.lo-ni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI 
and/or provided clinical data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can 
be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Declaration of interest
This work was supported by funding from Franciscan St. Francis Health, Indianapolis, IN and IPCo, Arlington, VA. Data collection 
and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health 
Grant U01 AG024904 and RC2 AG036535) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is 
funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous 
contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec, 
Inc.; Bristol-Myers Squibb Company; Eisai, Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd. and 
its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research 
& Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso 
Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc 
Inc. and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical 
sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The 
grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s 
Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro 
Imaging at the University of California, Los Angeles. Additional support to AJS was provided by NIH grants RC2 AG036535, R01 
AG19771, P30 AG10133, and R01 LM011360.
The authors declare no conflict of interest.
HHS Public Access
Author manuscript
Autoimmunity. Author manuscript; available in PMC 2016 August 01.
Published in final edited form as:









samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment 
(MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. 
Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by 
ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic 
group were significantly reduced compared to HC. However, the sera from the MCI population 
contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The 
data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for 
detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an 
individual for increases in R-RAA aPL over a previously established baseline may serve as a 
useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of 
the Alzheimer’s type.
Keywords
ELISA; mild cognitive impairment; neurodegenerative disease; redox-reactive antiphospholipid 
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Introduction
Treating Alzheimer’s disease (AD) before the first appearance of cognitive symptomatology 
is widely considered to be essential in maximizing therapeutic benefit of compounds 
currently under development that are aimed at either halting disease progression and/or at 
least modifying the rate of cognitive decline [1]. The sensitivities of cerebrospinal fluid 
(CSF) biomarkers and brain imaging technologies to detect early stage AD and progression 
are improving, but fall short of being used as standard screening techniques. At present there 
are no established biomarkers in blood that have been replicated in larger studies and have 
proven useful clinically to identify individuals at risk for developing AD.
Several serum markers have been described which may arise from inflammatory events in 
the central nervous system in the early course of AD [2–11]. Approaches using serum matrix 
analysis of multiple analytes [12–17] show promise in developing early detection biomarker 
panels incorporating both inflammatory and other protein biomarkers in the serum. Analysis 
of plasma exosomal content for microRNA (miRNA) [18,19] and pathogenic proteins 
[20,21] are currently undergoing evaluation for early diagnosis of AD.
At present, the fundamental pathophysiological events that give rise to neuronal cell death in 
AD are unknown. Bruce-Keller and co-workers [22] have reported significant elevations in 
NADPH oxidase (NOX) activity in the temporal gyri of mild cognitive impairment (MCI) 
patients. There are also confirmed studies to show that oxidative stress, in both brain and 
peripheral tissues, is one hallmark of early stage AD in cognitively impaired patients 
[23,24]. Of special interest are studies that document increased redox-reactive iron in the 
brains, CSF and peripheral tissues of MCI patients, which correlates with accumulation of 
free radical damage and parallels closely to the degree of cognitive impairment in these 
subjects [25].
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Recently, it was shown that 92% of all human sera tested contain brain-reactive 
autoantibodies; with an increased prevalence of brain-reactive antibodies in AD [26]. These 
data indicate that the humoral immune system is active within the neuropil, and that 
antibodies readily cross the blood brain barrier (BBB) [27] between the CNS and the blood. 
Further, in animal models of multiple sclerosis, components of the neuronal cytoskeleton 
released into the blood during neu-roaxonal loss give rise to neurofilament specific 
autoantibo-dies [28]. The discovery of the presence of serum α-synuclein autoantibodies in 
AD and in Dementia with Lewy Bodies (DLB) further reinforces this concept [27]. There is 
evidence that antiphospholipid (aPL) redox-reactive autoantibodies (R-RAA) are present in 
both serum and CSF of healthy individuals [29,30]. Certain aPL bind to epitopes on PL in 
the presence of specific PL-binding plasma proteins; these aPL are designated as aPL-
dependent (aPLd). Other aPL autoantibodies bind directly to epitopes on the PL, and are 
independent of PL-binding plasma proteins (aPLi). The separate activities can be 
distinguished in the ELISA by using either 10% adult bovine plasma to provide the 
necessary PL-binding proteins, or 1% BSA as serum diluents [31].
R-RAA aPLi and aPLd shown to be unmasked by treatment with a redox reactive reagent 
(hemin) include anti-phosphatidylserine (aPS), anti-cardiolipin (aCL), anti-phosphatidy-
lethanolamine (aPE) and anti-phosphatidylcholine (aPC), and are present in the CSF from 
healthy control (HC) individuals, but in comparison are significantly decreased in CSF taken 
from autopsy-confirmed Alzheimer’s patients (AD) [32,33]. This study was followed by the 
analysis of serum samples from subjects diagnosed with AD and age-matched HC [31]. R-
RAA aPL were significantly reduced in the sera from 16 subjects diagnosed with AD 
compared to 17 age-matched HC. Furthermore, the data from the serum study were analyzed 
using classification and regression tree (CART) analysis to identify R-RAA aPL 
discriminators to classify subjects within the two groups. The ELISA data from two analytes 
(IgG aPEi and IgM aPEd) were able to predict subjects with AD with 100% specificity and 
84% sensitivity [31].
While the discrimination between HC and AD by serum R-RAA aPL measurement provides 
the opportunity to identify a novel biomarker for assessing disease progression, the goal of 
the current study was to identify clinically useful serum biomarkers that appear prior to 
onset of cognitive decline. For this reason, serum samples from subjects diagnosed with 
MCI were included in the present study.
Methods
Serum samples
A pilot study was initiated with coded serum samples from 18 subjects assigned to each of 
three diagnostic groups (n = 6) by the Alzheimer’s Disease Neuroimaging Initiative (ADNI, 
see Appendix) (HC, MCI and AD). The samples were received on dry ice, and stored at −80 
°C until tested. On completion of ELISA analysis of the R-RAA data from these sera, 
subject diagnostic group assignment information were obtained from the ADNI and matched 
to the ELISA data to determine if a predictive relationship between serum R-RAA aPL and 
cognitive status would justify validation in an independent follow-up with a larger sample 
set.
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The follow-up study was initiated with coded serum samples from 90 subjects, assigned by 
ADNI to three diagnostic groups (n = 30) (HC, MCI and AD). After the R-RAA assay 
results from the blinded serum samples were released to ADNI, the R-RAA aPL data used in 
the preparation of this manuscript were matched to the participant diagnosis, demographic 
data and MMSE scores by accessing the ADNI sample database (adni.loni.usc.edu).
Sample preparation
Pilot study—Hemin chloride (Fe3+Cl) at 80–90% purity (Sigma Chemical Co., St. Louis, 
MO) was used to prepare a 112 mM solution of hematin (Fe3+OH) stock solution by 
dissolving hemin powder in 1 M NaOH with gentle stirring for 2 h, and then filtering 
through a Whatman #1 filter followed by storage at 4 °C. The concentration of the hematin 
solution was determined from the extinction coefficient of the monomer absorption maxima 
(385 nm) of 5840 M−1cm−1 [34], and remained stable for a period of at least 4 months.
The coded ADNI serum samples (0.5 ml) were thawed and divided equally into two 
aliquots. Immediately before hemin treatment of the serum either hematin in 1 M NaOH or 1 
M control NaOH solution were slowly added to stirred buffers containing 20 mM Tris, 151 
mM NaC1, 3 mM NaN3 (TBS), pH 7.8. The final pH of the hemin or control buffers was 
adjusted to 7.8 and 0.1 ml aliquots of thawed serum samples were mixed with 0.9 ml of 
hemin and control buffer. The samples were incubated for 20 h on a rocking platform at 
36°C then stored at −80 °C until ELISA analysis.
Follow-up study—Based on the encouraging results obtained in the pilot study, the ADNI 
provided samples for a follow-up study (vide infra). During the period between these 
studies, we had the opportunity to more carefully evaluate protocols and methods to 
optimize conditions for processing serum samples for R-RAA aPL analysis. A more pure 
source of hemin (≥99%, Frontier Scientific, Logan, UT) replaced the Sigma product used in 
the pilot studies. With each change in methodology, bridging studies using a set of serum 
samples from five HC donors frozen in multiple aliquots were used to determine the rank 
order OD output in each aPL ELISA assay. The R-RAA preparation protocol previously 
described [35] was used with modifications.
Aliquots of the 90 ADNI serum samples were thawed and treated with Cleanascite™ 
(Biotech Support Group, Inc., North Brunswick, NJ) at a serum: Cleanascite™ ratio of 4:1 
v/v in 2 ml micro centrifuge tubes with gentle rocking at 37 °C for 10 min followed by 
centrifugation for 1 min at 16 000 g. Treatment with Cleanascite™ removes lipoproteins 
from the serum, which have been shown to bind and undergo oxidation by hemin [36]. The 
supernatants were carefully aspirated, and divided into two aliquots for treatment with or 
without hemin as before. A hematin solution (130 mM) in 1 M NaOH was made from the 
Frontier hemin powder, using the spectro-photometric analysis described for the pilot study 
to determine the concentration. A 0.45 μm Acrodisc PDF filter (Pall Life Sciences, Port 
Washington, NY) was used for the filtration step. An aliquot of the stock hematin solution 
was diluted in TBS and the pH adjusted to 7.8 with 1 M HCl (final hemin concentration = 
1.28 mM). A control buffer without hemin was prepared using the same volume of 1 M 
NaOH and adjusted to pH 7.8 as above. Serum aliquots from each subject were separately 
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diluted 1:15 v/v in the hemin and control TBS buffers, gently rocked for 3 h at 37 °C, then 
stored frozen at −80 °C until ELISA analysis.
aPL ELISA
The thawed hemin-treated and buffer control-treated samples were separately diluted in 1% 
bovine serum albumin (BSA) or 10% adult bovine plasma (ABP) as previously described 
[31] to a final serum dilution of 1:100 for ELISA analyses. The buffers supplemented with 
ABP provide PL-binding plasma proteins that after binding to the PL undergo 
conformational changes that expose the target for aPL autoantibodies [37]. The plasma 
proteins which bind to cardiolipin (CL) are β2-glycoprotein I and prothrombin, whereas 
phosphatidyletha-nolamine (PE) is bound by high and low molecular weight kininogens 
[38]. aPL dependent upon PL-binding plasma proteins are designated in this study as aPLd. 
In the BSA supplemented buffer, the autoantibodies recognize the phospholipid independent 
of plasma proteins [39]. These aPL are designated as aPLi in this study. Three autoantibody 
isotypes (IgG, IgM and IgA) of aPLd and aPLi were assessed for reactivity against 
phosphatidylserine (PS), CL, PE and phosphatidylcholine (PC). All samples were tested in 
triplicate. For the pilot study, the ELISA methodology was conducted exactly as previously 
described [31]. The colorimetric readout from the ELISA assay was performed by 
incubation at 37 °C until OD of the standard positive control aPL reached ~1.0. R-RAA aPL 
activity was expressed as the OD difference between hemin-treated and buffer control-
treated values for each sample.
For the follow-up study, dilutions of each aPL positive control were used to construct a 
calibration curve on each ELISA plate. As before, the colorimetric readout from the ELISA 
assay was performed by incubation at 37 °C until OD of the highest standard positive 
control aPL reached ~1.0. The values for the hemin-treated and buffer control-treated 
samples were interpolated from a standard curve constructed using a second-order 
polynomial to fit the positive control data points. The R-RAA activity (in interpolated OD 
units) was expressed as the OD difference between hemin-treated and buffer control-treated 
values for each sample. As there is no absolute method to quantify the R-RAA aPL ELISA 
results, the ordinates are scaled to “interpolated OD units”.
Statistical analysis of data
Statistical analysis of R-RAA aPL OD values in the three groups of subjects (HC, MCI and 
AD) were performed using one way ANOVA, with Tukey post hoc tests of all pairs [40]. 
Significant p values are indicated in Figures 1 and 2. R-RAA aPL OD values analyzed by 
ANOVA passed the test of homogeneity of variance, with the exception of R-RAA aPCi in 
the follow-up study. In this case, following a Johnson transformation of the OD data, equal 
variance was achieved [40].
A goal of the pilot study was to determine if an in-sample discriminant model using subsets 
of R-RAA aPL data could construct a reasonable model for use in the follow-up study to 
assess the strength and utility of a predictive relationship of serum R-RAA aPL with AD-
related cognitive decline. The machine learning software known as Classification and 
Regression Trees, CART, implemented using the WEKA Data Mining Software [41] and 
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based on Breiman’s original algorithm [42], was used to create an inductive decision tree to 
classify the sample subjects. An inductive decision tree is a set of rules represented by 
decisional nodes and leaves (i.e. terminal nodes) that are assigned to a class. The learning 
process consists of selecting the most discriminative variable according to an impurity 
function to partition the data, and repeating this partition recursively until the nodes are 
considered pure enough to be terminal and then pruning the resultant complete tree to avoid 
over fitting.
Mini-mental state examination (MMSE) scores were used by the ADNI to assign study 
subjects. Following completion of the ELISA data analysis, baseline MMSE scores of the 90 
participating subjects (obtained from the ADNI database) were statistically analyzed for 
significance using the Student–Newman–Keuls Multiple Comparisons Test. Significance 




By far the most robust differences between R-RAA aPL were observed within the IgG 
isotype. Trends in differences in R-RAA aPL between AD and HC were apparent for both 
IgA and IgM ELISA data, but, because the OD values for the IgA and IgM data were very 
low, only the IgG R-RAA aPL data are presented in this study.
The R-RAA aPEi OD values for the AD group were significantly reduced compared to both 
the MCI and HC groups (Figure 1, panel A). This confirms the observation from our 
previous study of HC and AD, wherein the IgG R-RAA aPEi was significantly reduced in 
the AD group compared to the healthy controls [31], and reflects a similar reduction in R-
RAA aPL observed in the CSF of autopsy confirmed AD subjects compared to HC [33].
In this pilot study robust increases in R-RAA aCLd, aPEd and aPCi were observed in the 
MCI diagnostic group compared to the HC and AD diagnostic groups (Figure 1, panels B–
D). The CART algorithms were used to attempt classification between HC and MCI rather 
than including the group with advanced disease (AD). This justified, as the R-RAA aPL 
response was biphasic with respect to disease progression, and as such classifying three 
phases of AD progression unnecessarily complicated classification statistical analysis. We 
therefore view R-RAA aPL data from patients with AD as integral to understanding the 
physiological relationship between these analytes and the patho-physiology of 
neurodegeneration, but uninformative in terms of diagnostic utility for advanced AD.
CART analysis of the pilot study by using R-RAA IgG aPL data sets from HC and MCI 
subjects to probe for aPL discriminators correctly classified all six subjects in each group 
using a single analyte (aPEd OD ≤ 0.154 = six HC subjects, and aPEd OD>0.154 = six MCI 
subjects) with 100% sensitivity and specificity. When the aPEd data set was removed and an 
independent CART analysis was performed on the remaining IgG aPL classes, aPCi 
emerged as a discriminator with 87.5% sensitivity and 83.5% specificity (OD ≤ 0.895 = five 
HC subjects and OD>0.895 = six MCI subjects with one HC subject misclassified). One 
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further round of CART analysis yielded IgG aCLd with OD ≤ 0.078 defined five HC 
subjects, and OD>0.078 included seven subjects (6 MCI, 1 HC) (sensitivity = 87.5% and 
specificity = 83.5%). As a first approximation, this pilot study provided a model for 
discrimination of MCI subjects from HC.
The validity of the predictor model built with the results from the pilot study used as a 
training set was tested with a separate set of samples used in a follow-up study. The 
hypothesis is that subjects with MCI have elevated R-RAA aPEd, aCLd and aPCi compared 
to HC.
Follow-up study
Demographics for the 90 subjects included in the follow-up study are shown in Table 1. In 
this follow-up study using serum samples of 30 subjects from each of the three diagnostic 
groups (n = 30), three of the eight IgG R-RAA aPL ELISA tests were significantly different 
between at least two diagnostic groups. The results in Figure 2 show R-RAA aPSd, aPEd and 
aPCi demonstrated significant elevation in the MCI group compared to HC, while R-RAA 
aPCi were significantly elevated in the MCI group compared to AD. In the follow-up study, 
quantitative elevation in the R-RAA aCLd, in the MCI group compared to HC and AD did 
not reach statistical significance (Figure 2, panel B).
Due to the biphasic distribution of R-RAA aPL ELISA values among HC and MCI and AD, 
CART analysis across all IgG R-RAA was performed only between the HC and MCI 
groups. The results of CART analysis of 30 HC and 30 MCI are shown in block diagram in 
Figure 3. Data obtained from three of the eight R-RAA aPL IgG analytes classified subjects 
as MCI with a sensitivity of 80.0% and specificity of 83.3%. The discriminators described in 
the pilot study by CART classification statistics, aPCi, aCLd and aPEd, are the three analytes 
identified in the follow-up study.
Follow-up study diagnostic outcomes
ADNI study subjects whose serum samples were tested in the R-RAA aPL assay were 
routinely evaluated using the standard ADNI protocols for an additional 2–3 years after 
serum collection. The MMSE score classifications for baseline and the most recent visit are 
shown in Figure 4. One subject assigned as AD at baseline was reassigned to MCI at the 
most recent visit. Inspection of the diagnostic data revealed that this subject had the highest 
baseline MMSE (28) within the AD diagnostic group and at 4 year follow-up, the subject’s 
MMSE score dropped to 26.
With a few exceptions, the AD group demonstrated cognitive decline over time. From the 90 
subjects evaluated in our study, seven HC converted to MCI, one HC converted to AD and 
14 MCI subjects converted to AD (Figure 4). Two subjects within the original MCI 
diagnostic groups were reclassified as HC upon follow-up as the subject’s MMSE scores 
appeared stable over time. The limitations in the MMSE tool for distinguishing HC from 
MCI in borderline cases are apparent in these two subjects.
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The increase of R-RAA aPL in MCI patients was demonstrated by exposure of serum to 
redox-reactive iron in the form of hemin. It is possible that hemin accumulation at sites of 
oxidative stress in the early phase of AD promotes formation of post-translationally 
modified autoantibodies to cellular components and these R-RAA aPL decline with disease 
progression. To support this hypothesis, hemin has been shown to bind immunoglobulins 
and to dramatically broaden their antigen binding repertoire [43].
Although little is known about the origin of R-RAA aPL, there is increasing evidence that in 
neurodegenerative diseases dysregulation of the cell membranes of dystrophic neurites can 
result in altered phospholipid profiles in the blood, particularly for PC and PE [44]. 
Externalization of the aminophospholipids (PS and PE) to the outer leaflet of the plasma 
membrane [45] and exposure of mitochondrial CL during neuronal apoptosis, initiated long 
before overt cognitive symptomatology is apparent may elicit an immune response to 
membrane phospholipids. The recent lipidomic mass spectrometry discovery of robust 
serum biomarker lipid profiles in AD subjects [46–48] reinforces the concept that alterations 
in phospholipid metabolism occur early in the prodromal phase of AD.
The concept of using autoantibodies in blood as biomarkers for neurological disturbances in 
the CNS is gaining acceptance. For example, antibodies against both physiological [26] and 
pathological proteins within the CNS are detectable in the blood [49,50]. The persistence 
and abundance of specific biomarker autoantibodies in the blood of neurological disease 
patients may be more disease specific and stable when compared to inflammatory molecule 
bio-markers in the same patients. Our approach to detect specific R-RAA aPL serum 
autoantibodies for biomarker selection may offer a unique opportunity to uncover very early 
pathological events in AD and other neurodegenerative diseases. Further studies are needed 
to explore the relationship between disease progression and R-RAA aPL titers.
The data presented in this study strongly support R-RAA aPL measurement as a promising 
serum biomarker for detection of early AD. Elevated serum levels of R-RAA aPL decline 
with disease progression to AD, as previously noted [31], and reflect a similar reduction in 
R-RAA aPL observed in the CSF of autopsy confirmed AD subjects compared to HC [33].
The biphasic response of serum R-RAA aPL biomarkers in studies with a small number of 
subjects progressing from pre-symptomatic through MCI to AD would be expected to result 
in some inter-study variation across diagnostic groups between the pilot and follow-up 
study. A second contributor to inter-study variability is that several subjects diagnosed with 
MCI at baseline did not progress to a definitive clinical diagnosis of AD by conclusion of 
the follow-up study (Figure 4). It is therefore possible that some of these subjects were 
suffering from neurodegenerative disease(s) other than AD.
Studies to assess fluctuations of serum biomarker levels from a larger population of subjects 
are anticipated to assess predictability of the R-RAA aPL biomarker for staging AD by 
analyzing measurements from serial serum samples. These data will determine whether the 
sensitivity for detection of early AD at the stage of MCI is enhanced by following the 
changes in the R-RAA aPL biomarker over time in a given individual.
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Further collaborative studies are anticipated to assess selectivity of the biomarker for AD 
versus other neurological diseases, thereby establishing the feasibility of developing the R-
RAA aPL diagnostic as a routine screening technology for individuals at risk for developing 
AD. As with any new biomarker diagnostic that has the potential for identifying individuals 
at risk for developing a life-threatening and disabling disease, acceptance will only come 
after the diagnostic yields are proven accurate and predictive when used in a large 
population of individuals over time.
Acknowledgments
We are indebted to Drs. Leslie Shaw and John Trojanowski (ADNI Biomarker Core Group) for selection of the 
samples for this study, and to Dr. Shannon Risacher for assistance with updated ADNI clinical data.
References
1. Alzheimer’s disease facts and figures. Alzheimers Dement. 2014; 10:1–76. [PubMed: 23871765] 
2. Alkalay A, Rabinovici GD, Zimmerman G, et al. Plasma acetylcholinesterase activity correlates 
with intracerebral beta-amyloid load. Curr Alzheimer Res. 2013; 10:48–56. [PubMed: 23157337] 
3. Alsadany MA, Shehata HH, Mohamad MI, Mahfouz RG. Histone deacetylases enzyme, copper, and 
IL-8 levels in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2013; 28:54–
61. [PubMed: 23242124] 
4. Bai L, Song N, Yu J, et al. Elevated plasma levels of soluble TNFRs and TACE activity in 
Alzheimer’s disease patients of Northern Han Chinese descent. Curr Alzheimer Res. 2013; 10:57–
62. [PubMed: 23368432] 
5. Honma T, Hatta K, Hitomi Y, et al. Increased systemic inflammatory interleukin-1ss and 
interleukin-6 during agitation as predictors of Alzheimer’s disease. Int J Geriatr Psychiatry. 2013; 
28:233–241. [PubMed: 22535710] 
6. Liang F, Jia J, Wang S, et al. Decreased plasma levels of soluble low density lipoprotein receptor-
related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products 
(sRAGE) in the clinical diagnosis of Alzheimer’s disease. J Clin Neurosci. 2013; 20:357–361. 
[PubMed: 23228658] 
7. Lopez N, Tormo C, De Blas I, et al. Oxidative stress in Alzheimer’s disease and mild cognitive 
impairment with high sensitivity and specificity. J Alzheimers Dis. 2013; 33:823–829. [PubMed: 
23076075] 
8. Huang CW, Wang SJ, Wu SJ, et al. Potential blood biomarker for disease severity in the taiwanese 
population with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2013; 28:75–83. 
[PubMed: 23230229] 
9. May JE, Pemberton RM, Hart JP, et al. Use of whole blood for analysis of disease-associated 
biomarkers. Anal Biochem. 2013; 437:59–61. [PubMed: 23467100] 
10. Leung R, Proitsi P, Simmons A, et al. Inflammatory proteins in plasma are associated with severity 
of Alzheimer’s disease. PLoS One. 2013; 8:e64971. [PubMed: 23762274] 
11. Laske C, Schmohl M, Leyhe T, et al. Immune profiling in blood identifies sTNF-R1 performing 
comparably well as bio-marker panels for classification of Alzheimer’s disease patients. J 
Alzheimers Dis. 2013; 34:367–375. [PubMed: 23207486] 
12. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer’s 
diagnosis based on plasma signaling proteins. Nat Med. 2007; 13:1359–1362. [PubMed: 
17934472] 
13. O’Bryant SE, Xiao G, Barber R, et al. A blood-based algorithm for the detection of Alzheimer’s 
disease. Dement Geriatr Cogn Disord. 2011; 32:55–62. [PubMed: 21865746] 
14. Soares HD, Potter WZ, Pickering E, et al. for the Biomarkers Consortium Alzheimer’s Disease 
Plasma Proteomics. Plasma biomarkers associated with the apolipoprotein E genotype and 
Alzheimer Disease. Arch Neurol. 2012; 69:1–8.
McIntyre et al. Page 9









15. Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer 
disease. Arch Neurol. 2012; 69:1318–1325. [PubMed: 22801742] 
16. Ray L, Khemka VK, Behera P, et al. Serum homocysteine, dehydroepiandrosterone sulphate and 
lipoprotein (a) in Alzheimer’s disease and vascular dementia. Aging Dis. 2013; 4:57–64. 
[PubMed: 23696950] 
17. Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma proteins predict conversion to dementia from 
prodromal disease. Alzheimers Dement. 2014; 6:799–807. [PubMed: 25012867] 
18. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source 
of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell 
Vesicles. 2014; 310.3402/jev.v3.23743
19. Bekris LM, Lutz F, Montine TJ, et al. MicroRNA in Alzheimer’s disease: an exploratory study in 
brain, cerebrospinal fluid and plasma. Biomarkers: Biochem Indicat Exposure Response Suscept 
Chem. 2013; 18:455–466.
20. Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimer’s disease 
by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. 
Alzheimers Dement. 201410.1016/j.jalz.2014.06.008
21. Kapogiannis D, Boxer A, Schwartz JB, et al. Dysfunctionally phosphorylated type 1 insulin 
receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. FASEB J. 
201410.1096/fj.14-262048
22. Bruce-Keller AJ, Gupta S, Parrino TE, et al. NOX activity is increased in mild cognitive 
impairment. Antioxid Redox Signal. 2010; 12:1371–1382. [PubMed: 19929442] 
23. Smith MA, Zhu X, Tabaton M, et al. Increased iron and free radical generation in preclinical 
Alzheimer disease and mild cognitive impairment. J Alzheimers Dis. 2010; 19:363–372. [PubMed: 
20061651] 
24. Padurariu M, Ciobica A, Hritcu L, et al. Changes of some oxidative stress markers in the serum of 
patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett. 2010; 469:6–10. 
[PubMed: 19914330] 
25. Lavados M, Guillon M, Mujica MC, et al. Mild cognitive impairment and Alzheimer patients 
display different levels of redox-active CSF iron. J Alzheimers Dis. 2008; 13:225–232. [PubMed: 
18376063] 
26. Levin EC, Acharya NK, Han M, et al. Brain-reactive autoantibodies are nearly ubiquitous in 
human sera and may be linked to pathology in the context of blood–brain barrier breakdown. Brain 
Res. 2010; 1345:221–232. [PubMed: 20546711] 
27. Koehler NK, Stransky E, Shing M, et al. Altered serum IgG levels to alpha-synuclein in dementia 
with lewy bodies and Alzheimer’s disease. PLoS One. 2013; 8:e64649. [PubMed: 23741358] 
28. Gnanapavan S, Grant D, Pryce G, et al. Neurofilament a biomarker of neurodegeneration in 
autoimmune encephalomyelitis. Autoimmunity. 2012; 45:298–303. [PubMed: 22276904] 
29. McIntyre JA, Wagenknecht DR, Faulk WP. Redox-reactive autoantibodies: detection and 
physiological relevance. Autoimmun Rev. 2006; 5:76–83. [PubMed: 16338215] 
30. McIntyre JA, Wagenknecht DR, Faulk WP. Autoantibodies unmasked by redox reactions. J 
Autoimmun. 2005; 24:311–317. [PubMed: 15927793] 
31. McIntyre JA, Wagenknecht DR, Ramsey CJ. Redox-reactive antiphospholipid antibody differences 
between serum from Alzheimer’s patients and age-matched controls. Autoimmunity. 2009; 
42:646–652. [PubMed: 19886736] 
32. McIntyre JA, Chapman J, Shavit E, Hamilton RL, Dekosky ST. Redox-reactive autoantibodies in 
Alzheimer’s patients’ cerebrospinal fluids: preliminary studies. Autoimmunity. 2007; 40:390–396. 
[PubMed: 17612901] 
33. McIntyre JA, Hamilton RL, DeKosky ST. Redox-reactive autoantibodies in cerebrospinal fluids. 
Ann N Y Acad Sci. 2007; 1109:296–302. [PubMed: 17785318] 
34. Li SD, Su YD, Li M, Zou CG. Hemin-mediated hemolysis in erythrocytes: effects of ascorbic acid 
and glutathione. Acta Biochim Biophys Sin. 2006; 38:63–69. [PubMed: 16395529] 
35. McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies: discovery, definitions, 
detection and disease. Prog Lipid Res. 2003; 42:176–237. [PubMed: 12689618] 
McIntyre et al. Page 10









36. Nishida T, Kummerow FA. Interaction of low-density lipoproteins of serum with hemin. J Lipid 
Res. 1962; 3:448–455.
37. Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: 
implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116:1336–
1343. [PubMed: 20462962] 
38. Sugi T, McIntyre JA. Autoantibodies to phosphati-dylethanolamine (PE) recognize a kininogen-PE 
complex. Blood. 1995; 86:3083–3089. [PubMed: 7579402] 
39. McIntyre JA, Wagenknecht DR, Sugi T. Phospholipid binding plasma proteins required for 
antiphospholipid antibody detection – an overview. Am J Reprod Immunol. 1997; 37:101–110. 
[PubMed: 9138443] 
40. Zar, JH. Biostatistical Analysis. Prentice-Hall, Inc; Upper Saddle River, New Jersey: 1999. 
41. Hall M, Eibe F, Holmes B, et al. The WEKA data mining software: an update. SIGKDD Explor. 
2009; 11:10–18.
42. Breiman, L.; Friedman, J.; Olshen, R.; Stone, C. Classification and Regression Trees. Wadsworth 
Publishing Co; Pacific Grove, CA: 1984. 
43. Dimitrov JD, Roumenina LT, Doltchinkova VR, et al. Antibodies use heme as a cofactor to extend 
their pathogen elimination activity and to acquire new effector functions. J Biol Chem. 2007; 
282:26696–26706. [PubMed: 17636257] 
44. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Combination of metabolomic and 
phospholipid-profiling approaches for the study of Alzheimer’s disease. J Proteomics. 2014; 
104:37–47. [PubMed: 24473279] 
45. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and 
conundrums. J Exp Med. 2010; 207:1807–1817. [PubMed: 20805564] 
46. Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids identify antecedent memory 
impairment in older adults. Nat Med. 2014; 20:415–418. [PubMed: 24608097] 
47. González-Domínguez R, García-Barrera T, Gómez-Ariza JL. Metabolomic study of lipids in serum 
for biomarker discovery in Alzheimer’s disease using direct infusion mass spectrometry. J Pharm 
Biomed Anal. 2014; 98:321–326. [PubMed: 24992214] 
48. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Using direct infusion mass 
spectrometry for serum metabolomics in Alzheimer’s disease. Anal Bioanal Chem. 2014; 
406:7137–7148. [PubMed: 25230597] 
49. Nagele E, Han M, Demarshall C, et al. Diagnosis of Alzheimer’s disease based on disease-specific 
autoantibody profiles in human sera. PLoS One. 2011; 6:e23112. [PubMed: 21826230] 
50. Maftei M, Thurm F, Schnack C, et al. Increased levels of antigen-bound beta-amyloid 
autoantibodies in serum and cere-brospinal fluid of Alzheimer’s disease patients. PLoS One. 2013; 
8:e68996. [PubMed: 23874844] 
Appendix
The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National 
Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), private pharmaceutical companies and non-profit organizations, as a 
$60 million, 5-year public–private partnership. The primary goal of ADNI has been to test 
whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), 
other biological markers and clinical and neuropsychological assessment can be combined to 
measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease 
(AD). Determination of sensitive and specific markers of very early AD progression is 
intended to aid researchers and clinicians to develop new treatments and monitor their 
effectiveness, as well as lessen the time and cost of clinical trials. The Principal Investigator 
of this initiative is Michael W. Weiner, MD, VA Medical Center and University of 
California – San Francisco. ADNI is the result of efforts of many co-investigators from a 
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broad range of academic institutions and private corporations, and subjects have been 
recruited from over 50 sites across the US and Canada. The initial goal of ADNI was to 
recruit 800 subjects but ADNI has been followed by ADNI-GO (RC2-AG036535) and 
ADNI-2. To date these three protocols have recruited over 1500 adults, aged 55–90, to 
participate in the research, consisting of cognitively normal older individuals, people with 
early or late MCI, and people with early AD. The follow up duration of each group is 
specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO (RC2 AG036535). Subjects 
originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. 
Additional support for data analysis was provided by NIH grants P30 AG10133 and RO1 
AG19771.
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ADNI pilot study (six subjects/group. Data = Mean ± SEM). Hemin unmasked redox 
reactive autoantibody (R-RAA) aPL activity in sera from healthy control subjects (HC, 
white bars) and subjects diagnosed either with Mild Cognitive Impairment (MCI, grey bars) 
or Alzheimer’s Disease (AD, black bars); as assessed by standardized cognitive tests (see 
text for details). ELISA OD values were normalized to positive control OD values (~1.0) 
from qualified lots of anti-phospholipid antisera within each ELISA assay. Intrinsic antibody 
activity (OD values of the same serum sample prepared in the absence of hemin and 
analyzed identically) is subtracted from the hemin-treated OD values to give the R-RAA 
aPL OD units for the serum samples reported in the figure.
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Hemin unmasked redox reactive autoantibody (R-RAA) activity in sera from healthy control 
subjects (HC, white bars) and subjects diagnosed either with Mild Cognitive Impairment 
(MCI, grey bars) or Alzheimer’s Disease (AD, black bars) as assessed by standardized 
cognitive tests (see Methods section for details). ELISA OD values for the subjects (Mean ± 
SEM, n = 90) were interpolated from standard curves constructed from qualified lots of anti-
phospholipid antisera as positive controls. Intrinsic antibody activity (interpolated OD 
values of the same serum sample prepared in the absence of hemin and analyzed identically) 
is subtracted from the hemin-treated interpolated OD values to give the R-RAA aPL OD 
units for the serum samples reported in the figure.
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Classification and regression tree (CART) analysis of R-RAA aPL from 60 serum samples 
from the ADNI [30 healthy control subjects (HC) and 30 subjects diagnosed with Mild 
Cognitive Impairment (MCI)].
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Diagnostic group assignments at last follow-up (white bars – HC, grey bars – MCI and black 
bars – AD) of a total of 30 subjects grouped by diagnostic group assignment at baseline. Of 
the two subjects assigned as MCI at baseline and HC at last follow-up, the first subject 
(baseline MMSE = 26) had a last follow-up at 6 months (MMSE score = 30). The second 
subject had a consistent MMSE score of 30 at 7, 13 and 19 and last follow-up at 25 months, 
and may have been incorrectly assigned in the database. The single subject assigned AD at 
baseline (MMSE score = 28) and subsequently reassigned MCI was followed up at 9, 18, 19, 
38 and 49 months with MMSE scores of 26, 29, 28, 28 and 26, respectively, indicating 
uncertainty in interpreting the subject’s assigned diagnostic groups from the MMSE scores 
alone.
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Table 1
Participant demographics.
Features HC MCI AD
Number of subjects 30 30 30
Age, years (SD) 76.90 ± 4.67§ 77.24 ± 6.77§ 77.41 ± 8.18§
Gender, male % 50.00 66.67 53.33
APOE-4 (% with at least 1 allele) 36.67 46.67 60.00
Baseline MMSE 29.33 ± 0.84 27.10 ± 2.17 23.5 ± 2.01
Last visit MMSE 29.00 ± 1.55§ 24.43 ± 6.19* 19.40 ± 6.07***
Abbreviations: HC, healthy control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination.
Analysis of variance of MMSE scores of the three groups at either baseline or at last visit were all significantly different from each other (p<0.001, 
Student–Newman–Keuls multiple comparisons test). Two-tailed t-test of MMSE between scores at baseline and last visit of each group are 
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